GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4D Molecular Therapeutics Inc (NAS:FDMT) » Definitions » Effective Interest Rate on Debt %

4D Molecular Therapeutics (4D Molecular Therapeutics) Effective Interest Rate on Debt % : 0.00% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is 4D Molecular Therapeutics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. 4D Molecular Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $0.00 Mil. 4D Molecular Therapeutics's average total debt for the quarter that ended in Mar. 2024 was $14.42 Mil. Therefore, 4D Molecular Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 0.00%.


4D Molecular Therapeutics Effective Interest Rate on Debt % Historical Data

The historical data trend for 4D Molecular Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4D Molecular Therapeutics Effective Interest Rate on Debt % Chart

4D Molecular Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial - - - - -

4D Molecular Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of 4D Molecular Therapeutics's Effective Interest Rate on Debt %

For the Biotechnology subindustry, 4D Molecular Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4D Molecular Therapeutics's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4D Molecular Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where 4D Molecular Therapeutics's Effective Interest Rate on Debt % falls into.



4D Molecular Therapeutics Effective Interest Rate on Debt % Calculation

4D Molecular Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  0/( (16.124+14.671)/ 2 )
=-1  *  0/15.3975
=0.00 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=13.469 + 2.655
=16.124

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=11.522 + 3.149
=14.671

4D Molecular Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2023 )+Total Debt  (Q: Mar. 2024 ))/ count )
=-1  *  0/( (14.671+14.171)/ 2 )
=-1  *  0/14.421
=0.00 %

where

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=11.522 + 3.149
=14.671

Total Debt  (Q: Mar. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=10.998 + 3.173
=14.171

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


4D Molecular Therapeutics  (NAS:FDMT) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


4D Molecular Therapeutics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of 4D Molecular Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


4D Molecular Therapeutics (4D Molecular Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 455, Emeryville, CA, USA, 94608
4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.
Executives
David Kirn director, officer: Chief Executive Officer C/O 4D MOLECULAR THERAPEUTICS INC., 5858 HORTON STREET #455, EMERYVILLE CA 94608
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Uneek Mehra officer: See Remarks C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Rose Sharon Shabet 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Portfolio Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Illiquid Investments Sub-master Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Jacob Chacko director C/O IGNYTA, INC., 11095 FLINTKOTE AVE., SUITE D, SAN DIEGO CA 92121
Scott Bizily officer: Chief Legal and HR Officer C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE CA 94608
Robert Young Kim officer: Chief Medical Officer C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE CA 94608
Noriyuki Kasahara director C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE CA 94608
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104

4D Molecular Therapeutics (4D Molecular Therapeutics) Headlines